gpt-dict.com

Manganese for Osteoporosis

Verdict: Weak, indirect evidence; not a proven treatment

Manganese is biologically involved in building bone, but no study has ever tested it on its own for osteoporosis. The evidence is too weak to recommend manganese supplements to prevent or treat the disease.

C 🟠 C Weak Evidence Published

🔬Why this grade7-layer evidence engine

The grade is weak because the human evidence is thin and almost entirely indirect. The single supportive trial, Strause and Saltman 1994 (PMID 8027856), gave 59 postmenopausal women a four-arm combination over two years; bone loss was halted only in the group taking calcium plus copper, zinc, and manganese together. Because manganese was never given alone, its specific contribution cannot be separated out, and the trial used bone density rather than fractures as its endpoint, had roughly 15 people per arm, and was industry-funded.

The rest is observational. A 1990 case-control study (PMID 2407097) found lower serum manganese in osteoporotic women, and a 2022 NHANES analysis of 14,180 adults (PMID 36269752) linked higher dietary manganese to better bone density in some subgroups. Both show association, not cause. Two reviews (PMID 32042399, PMID 24470093) confirm no isolated manganese trial exists and flag a narrow safety margin, since high intake is neurotoxic.

Regulators support manganese only as a nutrient, not as an osteoporosis therapy. The FDA lists it simply as a 'nutrient supplement,' and EFSA's claim that it 'contributes to the maintenance of normal bones' is a generic nutrition statement, not a disease treatment. The NHS notes a balanced diet supplies enough and warns against high-dose use, and the WHO cautions about neurotoxicity. Mainstream osteoporosis guidelines do not recommend it.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.48
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Published
Confidence
81%
Highly consistent evidence
Evidence level
E7
Single small RCT

How strongly each layer supports this effect

lower = less supportive
L2 PubMedPrimary literature
0.40
L1 ExamineGlobal benchmark
0.50
L3 MechanismPlausibility
0.50
L11 AI re-checkIndependent read
0.50
L5 Clinical bodiesAuthoritative stance
0.55
Against Mixed Supports
▸View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.482
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 無高階證據可裁決
  4. tier_strict_requirement_check — Tier 條件達標，未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (5)L2 · primary research & systematic reviews

Spinal bone loss in postmenopausal women supplemented with calcium and trace minerals
PMID: 8027856 1994 隨機對照試驗 n = 59
Finding: Spinal BMD declined significantly in the placebo group. The combined calcium + trace minerals (Cu/Zn/Mn) arm was the only group in which bone loss was halted (no significant decline from baseline). Calcium alone or trace minerals alone produced intermediate, non-significant trends. The trial CANNOT isolate a manganese-specific effect — manganese was always co-administered with copper and zinc, and the only positive arm also contained calcium. Small sample per arm (~15) and surrogate endpoint (BMD, not fracture).
🟠 Limited quality ⚠️ Industry-funded Effect size: Spinal BMD change over 2y: placebo −3.5%, Ca-only −1.9% (NS), trace-mineral-only −1.6% (NS), Ca + trace minerals +1.3% (significant vs placebo). Manganese contribution not separable.
View on PubMed
Lower serum manganese concentrations in patients with osteoporosis
PMID: 2407097 1990 Other n = 39
Finding: Osteoporotic women had serum manganese roughly 25% of age-matched controls and showed a 4-fold greater rise in plasma manganese after an oral manganese challenge, suggesting lower manganese status. This is a small case-control association — it does NOT demonstrate that manganese supplementation prevents or treats osteoporosis, only that low manganese status may correlate with the disease.
🟠 Limited quality Academic Effect size: Mean serum Mn substantially lower in osteoporotic group; no clinical endpoint
View on PubMed
Trace Elements in Human Nutrition (II) - An Update
PMID: 32042399 2020 Other
Finding: Reviews mechanistic role of manganese as a cofactor for glycosyltransferases involved in proteoglycan synthesis in cartilage and bone matrix, and cites the Strause/Saltman 1994 trial as the principal human bone-supplementation evidence. Concludes that isolated manganese RCTs in osteoporosis are absent and that any bone benefit cannot be separated from co-administered minerals. Mechanistic narrative; no quantitative pooling, no GRADE.
🟠 Limited quality Academic Effect size: Not a quantitative review
View on PubMed
Manganese in health and disease
PMID: 24470093 2013 Other
Finding: Notes that overt manganese deficiency in humans is exceedingly rare and that bone-related evidence for supplementation rests largely on a single small combination trial (Strause 1994) plus animal data on cartilage proteoglycan synthesis. Authors emphasize that the narrow window between adequacy (~1.8-2.3 mg/day AI) and neurotoxic exposure cautions against routine supplementation. No supportive evidence for isolated manganese as an osteoporosis intervention.
Academic Effect size: Qualitative; cautionary on supplementation
View on PubMed
Relationship between blood manganese and bone mineral density and bone mineral content in adults: A population-based cross-sectional study
PMID: 36269752 2022 Other n = 14,180
Finding: Reported a non-linear association: higher dietary manganese intake was associated with higher BMD at the femoral neck and lower odds of osteoporosis in certain subgroups (notably postmenopausal women), with a possible inverted-U pattern. Cross-sectional design CANNOT establish causality; dietary manganese co-varies with overall diet quality, fruit/vegetable/whole-grain intake, and other minerals. No supplementation intervention.
🟠 Limited quality Academic Effect size: Adjusted odds ratios in subgroups; not from an interventional trial
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Supportive
NUTRIENT SUPPLEMENT source↗
L4b EU EFSA
Supportive
contributes to normal energy-yielding metabolism; contributes to the maintenance of normal bones; contributes to the normal formation of connective tissue; contributes to the protection of cells from oxidative stress source↗
L4c UK NHS
Cautious
You should be able to get all the manganese you need from your daily diet. Taking high doses of manganese for long periods of time might cause muscle pain, nerve damage and other symptoms, such as fatigue and depression. For most people, taking 4mg or less of manganese supplements a day is unlikely to cause any harm. For older people, who may be more sensitive to manganese, taking 0.5mg or less… source↗
L4d TW TFDA / 衛福部
Supportive
形態屬膠囊狀、錠狀且標示有每日食用限量之食品，在每日食用量中，其錳之總含量不得高於11 mg。限於補充食品中不足之營養素時使用。 source↗
L4e WHO
Cautious
A provisional guideline value of 0.08 mg/L for manganese in drinking-water is established based on neurological effects in rats; emerging evidence supports the oral route as a potentially important route of exposure for manganese toxicity. source↗
L5a NIH Office of Dietary Supplements
Cautious
Manganese is an essential trace element that is naturally present in many foods and available as a dietary supplement. Manganese is a cofactor for many enzymes, including manganese superoxide dismutase, arginase, and pyruvate carboxylase. Through the action of these enzymes, manganese is involved in amino acid, cholesterol, glucose, and carbohydrate metabolism; reactive oxygen species scavengin… source↗
L5b Mayo Clinic
Neutral
L5c Cleveland Clinic
Neutral
✓PMID 100% verifiedevery citation checked via NCBI Entrez
🔬5 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-osteoporosis-INT-manganese-001 繁體中文版 →